FONTANA DILETTA

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Detail

Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante Varillas, S. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. PLOS ONE, 20(1) [10.1371/journal.pone.0308747]. Detail

Fontana, D., Crespiatico, I., Zaghi, M., Mastini, C., D’Aliberti, D., Mauri, M., et al. (2024). First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis. Intervento presentato a: Forum nazionale sulla Medicina di Precisione. Il Modello HEAL ITALIA e il contributo della Ricerca al Sistema Sanitario del Futuro, Palermo, Italia. Detail

Malighetti, F., Villa, M., Sala, E., Geeta, G., Arosio, G., Gemelli, M., et al. (2024). Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy. Intervento presentato a: American Association for Cancer Research Annual Meeting 2024 - April 5-10, 2024, San Diego, CA [10.1158/1538-7445.am2024-987]. Detail

Fontana, D., Zambrotta, G., Scannella, A., Piazza, R., Gambacorti-Passerini, C. (2024). Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. ANNALS OF HEMATOLOGY, 103(5), 1561-1568 [10.1007/s00277-024-05649-4]. Detail